Business Trends– category –
-
Trump Executive Order Mandates Accelerated PQC Migration for Federal Agencies: Key Establishment by End of 2030, Digital Signatures by End of 2031 for High-Value Assets
TechTarget USA Overview President Trump issued an executive order accelerating the U.S. government's migration to post-quantum cryptography (PQC), setting binding deadlines of December 31, 2030, for key establishment and December 31, 203... -
Atom Computing Secures Series C Funding with NVentures Participation, Accelerating Logical Error Correction Development with Microsoft Collaboration
New Market Pitch USA Overview Atom Computing completed its Series C funding round in June 2026, with NVentures, NVIDIA's venture arm, joining as a strategic investor. The company continues active development, including a partnership with... -
Trump Administration Mandates Strict Deadlines for Federal Agencies to Migrate to Post-Quantum Cryptography: Key Establishment by End-2030, Digital Signatures by End-2031
MeriTalk USA Overview President Trump signed an Executive Order setting stringent deadlines for federal agencies to transition high-value assets and high-impact systems to Post-Quantum Cryptography (PQC). Key establishment must migrate b... -
U.S. DOE and White House Launch ‘Quantum Genesis’ Initiative to Develop Fault-Tolerant Quantum Computers by 2028, Accelerating National Quantum Strategy
U.S. Department of Energy USA Overview The U.S. Department of Energy (DOE) has announced the 'Quantum Genesis' initiative, aiming to develop and deploy the world's first scientifically relevant, fault-tolerant quantum computing capabilit... -
CAR-T Cell Therapy for Autoimmune Diseases Achieves 40-60% Cost Reduction and Sub-7-Day Manufacturing Through Gene Editing and Process Optimization
Market Intelo USA Overview Advances in gene-editing technologies are significantly reducing alloreactivity risk in allogeneic CAR-T products and cutting production costs by an estimated 40-60%. Next-generation allogeneic platforms aim to... -
Syntax Bio and Applied StemCell Partner to Accelerate Allogeneic Cell Therapies with GMP-Compliant Hypoimmune iPSCs and Cellgorithm Platform
CRISPR Medicine News USA Overview Syntax Bio and Applied StemCell have forged a strategic collaboration to propel next-generation regenerative medicine by advancing stem cell innovation. Applied StemCell will supply GMP-compatible hypoim... -
Bioprocessing Technologies Reshape Food Production, Environmental Applications, and Sustainable Manufacturing Beyond Pharma
Technology Networks Global Overview Bioprocessing technologies are redefining various industries beyond pharmaceuticals, including food production, environmental applications, and sustainable manufacturing. Key technologies like fermenta... -
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stemchymal® Stem Cell Therapy for Spinocerebellar Ataxia (SCA3 and SCA6)
BioSpace Japan Overview REPROCELL Inc. has submitted an application for manufacturing and marketing approval in Japan for its regenerative medicine product, Stemchymal®, aimed at inhibiting the progression of motor ataxia in patients wit... -
UniXell Biotechnology Secures US FDA IND Clearance for Off-the-Shelf Parkinson’s Cell Therapy UX-DA003, Accelerating Dual China-US Clinical Development
BioPharma APAC USA Overview UniXell Biotechnology announced that its allogeneic iPSC-derived therapy UX-DA003 for Parkinson's disease has received Investigational New Drug (IND) approval from the US FDA. This approval enables the company... -
Syntax Bio & Applied StemCell Partner to Accelerate Allogeneic iPSC Therapies with Low-Immunogenicity Lines and Cellgorithm Platform
Manufacturing Chemist USA Overview Syntax Bio and Applied StemCell have formed a strategic partnership to accelerate programmable iPSC therapy development. This collaboration aims to address key challenges of immune recognition and manuf...
